ADVFN Logo
Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

KTRA Kintara Therapeutics Inc

0.1209
0.0143 (13.41%)
Apr 19 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 7,271,216
Bid Price 0.1209
Ask Price 0.1218
News -
Day High 0.128

Low
0.081

52 Week Range

High
5.98

Day Low 0.1153
Company Name Stock Ticker Symbol Market Type
Kintara Therapeutics Inc KTRA NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.0143 13.41% 0.1209 19:59:57
Open Price Low Price High Price Close Price Prev Close
0.1195 0.1153 0.128 0.1214 0.1066
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
9,921 7,271,216 $ 0.1223985 $ 889,986 - 0.081 - 5.98
Last Trade Time Type Quantity Stock Price Currency
19:59:23 formt 200 $ 0.1209 USD

Kintara Therapeutics Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
4.68M 39.04M - 0 -15.02M -0.38 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Kintara Therapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No KTRA Message Board. Create One! See More Posts on KTRA Message Board See More Message Board Posts

Historical KTRA Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.11970.12880.1010.11346342,672,6440.00121.00%
1 Month0.09040.240.0860.148285917,890,9640.030533.74%
3 Months0.12980.240.0810.125592614,497,034-0.0089-6.86%
6 Months4.254.58610.0810.14485499,579,240-4.13-97.16%
1 Year3.395.980.0810.18556054,839,457-3.27-96.43%
3 Years69.50142.500.08110.652,655,654-69.38-99.83%
5 Years60.50167.500.08115.152,295,361-60.38-99.80%

Kintara Therapeutics Description

Kintara Therapeutics Inc is engaged in the development of novel cancer therapies for patients with unmet medical needs. The company is developing two late-stage, Phase 3-ready therapeutics for clear unmet medical needs with reduced risk development programs. The two programs are VAL-083 for GBM and REM-001 for CMBC. VAL-083 is a small-molecule chemotherapeutic with a novel mechanism of action that has demonstrated clinical activity against a range of cancers, including the central nervous system, ovarian, and other solid tumors. The company is also advancing its proprietary late stage photodynamic therapy (PDT) platform that holds promise as a localized cutaneous or visceral tumor treatment as well as in other potential indications.

Your Recent History

Delayed Upgrade Clock